key: cord-0969523-lvulom93 authors: Joseph, Tobin; Crawley, Eleanor; Qamar, Sulmaaz; Zosmer, Maya; Rayanagoudar, Girish; Nethaji, Chidambaram; Menon, Ravi title: Diabetic emergencies presenting during the COVID‐19 pandemic: A retrospective case analysis date: 2021-10-29 journal: Endocrinol Diabetes Metab DOI: 10.1002/edm2.313 sha: dd967060b22eaade26622f400bcafc6a46f40c12 doc_id: 969523 cord_uid: lvulom93 INTRODUCTION: COVID‐19 has triggered a global pandemic and is an emerging situation. Diabetes has been associated with significant mortality in SARS and MERS‐COV infections. Patients with diabetes are at risk of COVID‐19 triggering diabetic emergencies due to known and unknown mechanisms. There is little evidence overviewing the clinical course of COVID‐19 patients who either present or have diabetic emergencies during their disease course. METHODS: We conducted a retrospective case analysis of all patients admitted to our hospital during the COVID‐19 pandemic. The inclusion criteria were all patients receiving treatment for COVID‐19 and either presenting with a diabetic emergency on admission or developing an emergency during their admission. Data collected for the study were all routinely collected data as part of the admission. We compared these data to nine patients with no COVID‐19. RESULTS: Thirty patients received treatment for a diabetic emergency, of which 21 also received treatment for COVID‐19. Significant differences were found between pH and bicarbonate on admission between RT‐PCR‐positive and both RT‐PCR‐negative and non‐COVID‐19 patients. Other results approaching significance include ALP and eGFR. DISCUSSION: Patients suffering from COVID‐19 and diabetes concurrently can suffer from profound metabolic disturbance, with a significant difference in inpatient mortality. However further, prospective detailed investigation into biochemical processes is needed to fully elucidate underlying mechanisms that affect these patients' outcomes. We conducted a retrospective case analysis of patients with diabetes admitted to the medical wards of North Middlesex Hospital, London, during the COVID-19 pandemic between 15 March and 15 April 2020. The inclusion criteria were: (1) positive swab testing for COVID-19, (2) admission due to a diabetic emergency. We recorded details regarding the length of hospital stay, features of the metabolic emergency, time until resolution, treatment pathways utilized, clinical course of the patient, clinical outcome at 7 days post admission. Data for the study were extracted from routine hospital records. Notes were manually reviewed for results as well as for follow-up information. The study was part of a departmental audit, evaluating treatment pathways for patients with diabetic emergencies during the pandemic, and has been approved by the Ethics Department of our Hospital. Primarily patients with clinical features matching the UK government case definition for COVID-19, 10 DKA: all of 1 blood glucose concentration >11mmol/l or known to have diabetes, 2 blood ketones >3.0 mmol/l, 3 venous pH <7.3 and/or bicarbonate concentration <15mmol/l 11 HHS: clinically hypovolaemic with markedly raised blood glucose concentration (>30 mmol/l), without hyperketonaemia (ketones <3 mmol/l) or acidosis (pH >7.3) with raised osmolality (> 320 mosmol/kg) 12 Mixed DKA/HHS: clinical overlap state where features are present from the above clinical syndromes. We also had a group of patients who underwent treatment for a diabetic emergency without being investigated or treated for COVID-19. These patients were used as comparators to investigate significant metabolic differences. Qualitative characteristics were presented as mean values ±standard deviation while quantitative characteristics were presented as percentages (%). Differences between groups were evaluated using independent student t-test. Statistical significance was set at the level of p-value <0.05. We have split the patients into RT-PCR swab positive and RT-PCR swab negative but treated with a high clinical suspicion. Kaplan-Meier survival graph was calculated based on length of stay in days for the three patient groups with death as the event. Thirty patients are included in this retrospective analysis, with their demographics demonstrated in Table 1 Seven patients were RT-PCR negative but treated for COVID-19 due to high degree of clinical suspicion. The average age was 47.33 ± 20.46 years, with five males and two females. 43% of these patients had type 1 diabetes. One patient had DKA, two had HHS, two had a mixed picture with one patient having hyperglycaemic ketosis. 67% of patients had been successfully discharged home within 7 days. For the patients who were not treated for COVID-19 (n = 9), all patients had DKA despite the fact that 33% had type 2 diabetes. There were four males and five females. 67% (n=6) of these patients were insulin treated, and 100% were discharged home within 7 days of admission. Table 2 demonstrates the admission gas results, blood tests and glycosylated haemoglobin (HbA1c) as well as selected COVID-19 markers. Broadly routine admission blood tests were similar when averaged and compared between the three groups. There was a non-significant rise in white cell count going from the RT-PCR patients to non-COVID-19 patients. No significant lymphopaenia was observed between any of the three groups. Kaplan-Meier survival curves were drawn for the groups, comparing all-cause mortality. This is shown in Figure 1 . It demonstrates that the cumulative survival time drops if being treated for COVID-19, and more so if treated for COVID yet RT-PCR negative. This is the first single-centre report on COVID-19-related diabetic emergencies. Some of the data in this study were part of the three-centre study which was published in Lancet Diabetes and Endocrinology recently. 13 We have observed that these pa- correlates with the observation that acute kidney injury (AKI) is more often observed in this cohort. 15 There was no difference in liver function tests unlike previous published trials. 16 disease severity. This was based on a retrospective study from Wuhan, the region of China first affected by COVID-19. 17 Our patients show elevated levels of these markers, with marginally reduced lymphocyte count, suggesting that there is severe metabolic derangement-however, whether this is due to COVID-19, the diabetic emergency or a combination is yet to be determined. Baseline Demographics of all patients that were management for both a diabetic emergency and COVID-19, including destination at 7 days Non-COVID−19 patients (n = 9) Age (years), mean ± SD 51. 21 Blood test result mean .828 .891 The values in bold were found to be statistically significant. Our study was small (n = 30) which makes statistical analyses difficult and can lead to false significance. However, the findings of our and need for interpreting results with caution. 18, 19 However, the only way to date to successfully test for COVID-19 is by RT-PCR of nasal swab, tracheal aspirate or bronchoalveolar lavage samples. 20 There are many barriers to the rapid roll out of serological tests including assessment of sensitivity and specificity of the tests, possibility of false-positive tests due to cross-reactivity with other viral pathogens and ensuring that mass production of the test is economically viable. 21 Another key limitation of this report is that this is a retrospective analysis of routinely collected data, meaning that there are some gaps in investigations. These primarily included lactate dehydrogenase, ferritin and aspartate transaminase in the non-COVID-19 patients and some of the patients treated during the COVID-19 pandemic. We present a single-centre observational analysis of COVID-19 patients who suffered from a diabetic emergency, in comparison to non-COVID-19 patients. Some significant differences were found; however, further investigations are needed into the relationship of COVID-19 and their impact on diabetic control and the risk of diabetic emergencies. A significant difference in mortality was observed. Prospectively collected data with a larger patient base, including data on COVID-19 markers, could help shed further light on the management of inpatient diabetics with COVID-19. Not applicable. Nothing to declare by any author. Writing-original draft (lead); Writing-review & editing (lead). We followed the NHS REC decision flowchart and in line with this guidance ethical approval was not sought. The NHS REC flowchart can be found at http://www.hra-decis ionto ols.org.uk/ethic s/. We felt that this vital information should be shared with the wider medical community and so a manuscript was prepared and submitted to BMC. Consent was not sought at the time of patient admission as they were not being enrolled into any study. This was part of a clinical audit registered with the trust for review of paper notes. All patient healthcare data were collected anonymously, retrospectively and no patient identifiable data were collected or described in the manuscript. This was in line with the NHS Health Research Authority guidance. 22 Available from authors on reasonable request. Tobin Joseph https://orcid.org/0000-0002-9283-9895 Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a wholepopulation study Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia -A systematic review, meta-analysis, and meta-regression Practical recommendations for the management of diabetes in patients with COVID-19 COncise adVice on Inpatient Diabetes (COVID:Diabetes): Front door guidance Euglycemic diabetic ketoacidosis: a diagnostic and therapeutic dilemma Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study COVID-19 and diabetes: knowledge in progress COVID-19: investigation and initial clinical management of possible cases Joint British Diabetes Societies guideline for the management of diabetic ketoacidosis: diabetic ketoacidosis guidelines Management of hyperosmolar hyperglycaemic state in adults with diabetes -Scott -2015 -Diabetic Medicine -Wiley Online Library Protracted ketonaemia in hyperglycaemic emergencies in COVID-19: a retrospective case series Proportion of newly diagnosed diabetes in COVID -19 patients: a systematic review and meta-analysis Management of acute kidney injury in patients with COVID-19. The Lancet Respiratory Medicine Abnormal liver function tests in COVID-19 patients: relevance and potential pathogenesis Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Real-time RT-PCR in COVID-19 detection: issues affecting the results Interpreting a covid-19 test result COVID-19 diagnosis and management: a comprehensive review The important role of serology for COVID-19 control Consent in research